Scarica l'app Stockscreener
9.6714
2.33%
0.2214
Precedente Chiudi:
$9.45
Aprire:
$9.55
Volume 24 ore:
58,326
Relative Volume:
0.06
Capitalizzazione di mercato:
$761.70M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-15.91%
1M Prestazione:
-29.11%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.38
$9.68
Intervallo di 1 settimana:
$9.32
$11.58
Portata 52W:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Nome
Niagen Bioscience Inc
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Confronta NAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
9.67 | 872.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.50 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.20 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.18 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.93 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.37 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
What drives Niagen Bioscience Inc. stock priceFree Investment Timing Strategies - Autocar Professional
Niagen Bioscience to Report Second Quarter 2025 Financial Result - GuruFocus
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - Business Wire
Is Niagen Bioscience Inc. a good long term investmentSignificant capital appreciation - Autocar Professional
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap dropped US$129m last week; individual investors who hold 33% were hit as were institutions - simplywall.st
What analysts say about Niagen Bioscience Inc. stockFree Consultation - Autocar Professional
Niagen Bioscience Inc. Stock Analysis and ForecastFree Stock Market Forecast Reports - jammulinksnews.com
Niagen Bioscience Shares Climb Following Exclusive License for Parkinson’s Therapy - MSN
Niagen Bioscience (NASDAQ:NAGE) Shares Down 4%Time to Sell? - MarketBeat
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Analysts Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Target Price at $13.22 - Defense World
How Niagen Bioscience Inc. stock performs during market volatilityROI Driven Alerts - Newser
What makes Niagen Bioscience Inc. stock price move sharplyFree Stock Market Group - Newser
Why Niagen Bioscience Inc. stock attracts strong analyst attentionTop Growth Low Risk Stocks - Newser
Niagen Bioscience shares fall 1.15% intraday after announcing Tru Niagen debut at Equinox Hotel New York. - AInvest
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York | NAGE Stock News - GuruFocus
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York - New Castle News
Niagen Bioscience signs exclusive licence deal for PD therapy - Yahoo Finance
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway - BioSpace
Niagen Bioscience (NAGE) Secures Exclusive License Agreement - GuruFocus
Niagen Bio signs license deal with Haukeland University (NAGE) - Seeking Alpha
Niagen Bioscience stock rises on exclusive Parkinson’s treatment license - Investing.com India
Niagen Bioscience secures exclusive rights for Parkinson’s treatment By Investing.com - Investing.com Nigeria
Niagen Bioscience secures exclusive rights for Parkinson’s treatment - Investing.com
Niagen Bioscience stock rises on exclusive Parkinson’s treatment license By Investing.com - Investing.com Nigeria
Niagen Bioscience Secures Exclusive License to Develop and Comme - GuruFocus
Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari
Non sono disponibili dati finanziari per Niagen Bioscience Inc (NAGE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Niagen Bioscience Inc Azioni (NAGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
4.56%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):